Combined hormonal contraceptive vaginal ring

Provenance

Written by SPS and the College of Sexual and Reproductive Healthcare (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.

Template versions available

Version 3.1 of this PGD template, valid from April 2026, has been published to allow organisations to undertake local governance processes in a timely manner.  Version 3.0 has been updated to reflect the revised UKMEC published in December 2025.

Version 2 of this PGD template remains currently valid and will be removed from this page on its expiry (31^st March 2026)

PGD template attachment

The template PGD is attached below to download and use in conjunction with our implementation advice (SPS page).

• CHC-ring-National-PGD-V2-FINAL-Nov 24Opens in a new window · Word · 193 KB
• CHC ring National PGD template accessible V3.1 01.26Opens in a new window · Word · 116 KB

Patient Group Directions, Templates, Reproductive health

• Ulipristal acetate 30mg tablets for emergency contraception
• Levonorgestrel 1500 microgram tablets for emergency contraception
• Medroxyprogesterone acetate (SC-DMPA) injection for contraception
• Combined hormonal contraceptive transdermal patch
• Progestogen only pill (POP) for contraception
• Lidocaine plus prilocaine cream for IUD insertion or removal
• Combined oral hormonal contraceptive (COC) in reproductive health
• Medroxyprogesterone acetate (DMPA) IM injection for contraception
• Lidocaine 10mg/ml spray for IUD insertion or removal
• Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
• Lidocaine injection for subdermal etonogestrel in contraception
• Etonogestrel (e.g. Nexplanon®) implant for contraception
• Copper Intrauterine Device (Cu-IUD)

Update history